Transcriptomics-based AI-enabled Drug Discovery
To Know
Where:
Online
Organizer:
NIH Rare Disease Informatics SIG
Presented By:
Bin Chen PhD (Michigan State University)
About this Class
A common drug-repurposing strategy for rare diseases is to identify compounds that reverse disease-associated transcriptomic signatures. Most existing approaches rely on large-scale resources such as the Connectivity Map (CMap) and LINCS. However, these databases were generated years ago and therefore do not include the rapidly growing number of newly developed investigational compounds. In addition, their drug-induced expression profiles are primarily derived from in vitro cell-line models, which may not fully capture in vivo drug responses. In this talk, Dr. Chen will present our recent efforts to address these limitations.